Drug Profile
RBB 004
Alternative Names: Fv-Hsp-72; RBB004Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Rubicon Biotechnology
- Developer Rubicon Biotechnology; Stein Eye Institute
- Class Anti-ischaemics; Eye disorder therapies; Ischaemic heart disorder therapies; Neuroprotectants; Recombinant fusion proteins
- Mechanism of Action Apoptosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain injuries; Myocardial infarction; Retinal artery occlusion
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Retinal-Artery-Occlusion in USA
- 28 Aug 2021 No recent reports of development identified for preclinical development in Brain injuries in USA
- 28 Aug 2021 No recent reports of development identified for preclinical development in Myocardial-infarction in USA